跳至主要内容
临床试验/NCT02156362
NCT02156362Unknown不适用

Determination of Pronostics Factors for Advanced Thyroid Carcinoma (pT3 pT4 or M1 at Diagnosis)

Hospices Civils de Lyon2 个研究点 分布在 1 个国家目标入组 643 人开始时间: 2012年5月最近更新:
适应症

试验速览

阶段
不适用
入组人数
643
试验地点
2
主要终点
Rate of Thyroid cancer evolving to refractory stage

研究概览

简要总结

It is generally estimated that 5 % of patients with thyroid cancer will develop distant metastases, and most of them had an advanced stage of the disease at presentation. Thirty per cent of them are resistant to radio iodine therapy and are called "refractory". Their long term survival is estimated to be less than 10 %.

The objective of this study is to identify the factors associated with poor outcome in a cohort of patients with advanced thyroid cancer followed during 5 years. Anaplastic and medullary thyroid carcinomas were excluded.

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Other
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Man or woman ≥ 18 years.
  • Thyroid cancer differentiated from follicular origins (papillary, vesicular or poorly differentiated carcinoma).
  • TNM classification: stage pT3 (≥2 cm), or pT4 or M1 at diagnosis.
  • Patient after post operative radioiodine therapy.

排除标准

  • Patient who can not be followed during the protocol.
  • Patient who does not consent.

结局指标

主要结局

Rate of Thyroid cancer evolving to refractory stage

时间窗: 5 years

次要结局

未报告次要终点

研究者

申办方类型
Other
责任方
Sponsor

研究点 (2)

Loading locations...

相似试验

Determination of Pronostics Factors for Advanced... | 临床试验